Robert W. Baird Boosts IQVIA (NYSE:IQV) Price Target to $256.00

IQVIA (NYSE:IQV) had its price target hoisted by Robert W. Baird from $251.00 to $256.00 in a research report report published on Friday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

IQV has been the topic of several other reports. Truist Financial raised their price target on IQVIA from $292.00 to $300.00 and gave the company a buy rating in a research report on Tuesday, July 23rd. UBS Group raised their target price on IQVIA from $295.00 to $300.00 and gave the company a buy rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. upped their price target on IQVIA from $260.00 to $288.00 and gave the stock an overweight rating in a report on Monday, August 5th. Evercore ISI raised their price objective on shares of IQVIA from $230.00 to $270.00 and gave the stock an outperform rating in a research note on Tuesday, July 23rd. Finally, Argus upgraded shares of IQVIA to a strong-buy rating in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $267.00.

IQVIA Stock Performance

Shares of NYSE IQV opened at $242.12 on Friday. The business’s 50-day simple moving average is $240.60 and its 200-day simple moving average is $233.94. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a market cap of $44.14 billion, a price-to-earnings ratio of 33.08, a P/E/G ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.22 earnings per share. As a group, equities research analysts expect that IQVIA will post 10.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA in the second quarter worth $27,000. Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA during the second quarter worth $29,000. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter valued at about $31,000. Finally, Riverview Trust Co acquired a new position in IQVIA during the 1st quarter worth about $32,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.